Citigroup’s Abiomed Inc ABMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-10,000
Closed -$3.59M 6796
2021
Q4
$3.59M Hold
10,000
﹤0.01% 2116
2021
Q3
$3.25M Hold
10,000
﹤0.01% 2112
2021
Q2
$3.12M Hold
10,000
﹤0.01% 2310
2021
Q1
$3.19M Sell
10,000
-84,700
-89% -$27.1M ﹤0.01% 2150
2020
Q4
$30.7M Sell
94,700
-6,900
-7% -$1.91M 0.02% 786
2020
Q3
$28.1M Sell
101,600
-30,800
-23% -$8.87M 0.02% 739
2020
Q2
$32M Sell
132,400
-19,800
-13% -$3.98M 0.03% 576
2020
Q1
$22.1M Buy
152,200
+75,200
+98% +$12.5M 0.02% 683
2019
Q4
$13.1M Sell
77,000
-6,300
-8% -$1.17M 0.01% 1255
2019
Q3
$14.8M Buy
83,300
+20,800
+33% +$4.5M 0.01% 1116
2019
Q2
$16.3M Sell
62,500
-6,400
-9% -$1.7M 0.01% 1062
2019
Q1
$19.7M Buy
68,900
+35,900
+109% +$11.9M 0.02% 838
2018
Q4
$10.7M Buy
33,000
+3,900
+13% +$1.35M 0.01% 1211
2018
Q3
$13.1M Buy
29,100
+24,800
+577% +$9.78M 0.01% 1104
2018
Q2
$1.76M Buy
4,300
+900
+26% +$326K ﹤0.01% 2793
2018
Q1
$989K Buy
3,400
+600
+21% +$152K ﹤0.01% 3248
2017
Q4
$525K Buy
2,800
+400
+17% +$74.7K ﹤0.01% 4046
2017
Q3
$405K Buy
2,400
+2,100
+700% +$318K ﹤0.01% 4327
2017
Q2
$43K Buy
+300
New +$40.3K ﹤0.01% 5896
2017
Q1
Sell
-2,800
Closed -$316K 7393
2016
Q4
$316K Buy
2,800
+2,000
+250% +$232K ﹤0.01% 4869
2016
Q3
$103K Buy
+800
New +$95.8K ﹤0.01% 5187

Other funds holding ABMD

Citigroup's ABMD Position: Q4 2022 in Review

Citigroup sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 40,942 shares — an estimated $10.1M sold.

Citigroup first reported a position in ABMD in Q2 2013 and held it in 38 quarters. The position peaked at $14.5M in Q4 2020. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • Citigroup reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • Citigroup sold 40,942 Abiomed Inc shares in Q4 2022, an estimated $10.1M.
  • Citigroup first reported a position in Abiomed Inc in Q2 2013 and held it in 38 quarters.
  • Citigroup's Abiomed Inc position peaked at $14.5M in Q4 2020.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on Citigroup's 13F filing for Q4 2022, filed 9 Feb 2023.